Leading in sustainability

Conference call and webcast for analysts, institutional investors and rating agencies

9 September 2020
Session is being recorded
Forward-looking statements disclaimer

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group’s control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failure to obtain, defend and enforce effective intellectual property (IP) protection and IP challenges by third parties; the impact of competitive pressures including expiry or loss of IP rights, and generic competition; the impact of price controls and reductions; the impact of economic, regulatory and political pressures; the impact of uncertainty and volatility in relation to the UK’s exit from the EU; the risk of failures or delays in the quality or execution of the Group’s commercial strategies; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group’s medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology, data protection or cybercrime; the risk of failure of critical processes; any expected gains from productivity initiatives are uncertain; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to adhere to applicable laws, rules and regulations; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; the risk of failure to adhere to increasingly stringent anti-bribery and anti-corruption legislation; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group’s financial position; and the impact that the COVID-19 global pandemic may have or continue to have on these risks, on the Group’s ability to continue to mitigate these risks, and on the Group’s operations, financial results or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.
Speakers

Leif Johansson
Non-Executive Chairman of the Board

Katarina Ageborg
Executive Vice-President, Sustainability and Chief Compliance Officer; President AstraZeneca AB, Sweden
Agenda

Commitment

Governance

Leadership

Closing and Q&A
Commitment to sustainability
Why is sustainability so important now?

The World Health Organization estimates that **air pollution kills 7 million people each year.**

In some high-income countries, cancer survival rates for children can be 80%. **In many low-income countries, it’s 20%.**

Plastic waste is found in the guts of more than **90% of the world’s sea birds.**

The World Economic Forum predicts that **it will take more than two centuries to achieve pay equality in the workplace.**
AstraZeneca’s commitment to sustainability

We use our capabilities to make the most meaningful impact where society needs it — health.

We believe there is a strong connection between the health of our patients, our business, our workforce, our communities and the planet, and each of these impact one another.
Governance of sustainability
Board of Directors
• Non-Executive Director Geneviève Berger oversees sustainability matters on behalf of the Board

Senior Executive Team (SET)
• Accountable for specific sustainability initiatives and review of the sustainability scorecard each quarter.
• SET Sustainability rep: Katarina Ageborg, EVP, Sustainability and Chief Compliance Officer, President AstraZeneca AB, Sweden

Sustainability Advisory Board
• SET members
• External sustainability experts
We have well defined priorities

<table>
<thead>
<tr>
<th>Access to Healthcare</th>
<th>Environmental Protection</th>
<th>Ethics and Transparence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Health is at the heart of our business</strong></td>
<td><strong>The health of the planet impacts all life</strong></td>
<td><strong>Healthy societies promote equality and prosperity for all</strong></td>
</tr>
<tr>
<td>Address the global burden of NCDs through a holistic approach – from prevention to pipeline to treatment</td>
<td>Manage our environmental impact across all our activities and our products</td>
<td>Create positive societal impact and promote ethical behaviour in all markets across our value chain</td>
</tr>
</tbody>
</table>

**Our ambitions for 2025**

**Our focus areas**

- Investments in health systems
- Affordability
- Responsible R&D
- Environment’s impact on health
- Disease prevention and treatment

- Product environmental stewardship
- Greenhouse gas reduction
- Pharmaceutical in the environment
- Water stewardship
- Waste management

- Ethical business culture
- Inclusion and diversity
- Talent and workforce evolution
- Workforce wellbeing and safety
- Responsible supply chain
- Human rights

Source: AstraZeneca Sustainability Report 2019
Leadership in sustainability
We can all make an impact

“...

At AstraZeneca, we all work to make the world a better place. We push the boundaries of science to deliver life-changing medicines to the people who need them.

Our focus on sustainability is integral to our efforts, and we continue to make advancements across our three priority areas – increasing access to healthcare, protecting the environment and demonstrating our commitment to ethics and transparency.”

Pascal Soriot
Executive Director and CEO
Our United Nations SDG impact

Access to Healthcare

Health is at the heart of our business

- SDG 3 – Good health and wellbeing
- SDG 8 – Decent work and economic growth
- SDG 17 – Partnership for the goals

Environmental Protection

The health of the planet impacts all life

- SDG 12 – Responsible consumption and production
- SDG 13 – Climate action
- SDG 17 – Partnership for the goals

Ethics and Transparency

Healthy societies promote equality and prosperity for all

- SDG 5 – Gender equality
- SDG 8 – Decent work and economic growth
- SDG 17 – Partnership for the goals

Source: AstraZeneca Sustainability Report 2019
Access to healthcare
Access to Healthcare

Health is at the heart of our business

We have a bold ambition: Work towards a future where all people have access to sustainable healthcare solutions for life-changing treatment and prevention

Supporting the UN Sustainable Development Goals

Our focus areas

- Disease prevention and treatment
- Responsible R&D
- Investments in health systems
- Environment’s impact on health
- Affordability

Source: AstraZeneca Sustainability Report 2019
Access to healthcare – impact

- **81,000+** healthcare workers trained (cumulative)
- **19.8m+** reached through access programmes (cumulative)
- **9.7m+** reached through Patient Assistance Programmes (cumulative)
- **UNGC** Patron sponsor of Business Ambition for Climate and Health

Source: AstraZeneca Sustainability Report 2019
Environmental protection
The health of the planet impacts all life

We have a bold ambition: Manage our environmental impact across all our activities and our products, working toward a restorative approach

Supporting the UN Sustainable Development Goals

Our focus areas:
- Product environmental stewardship
- Pharmaceuticals in the environment
- Greenhouse gas reduction
- Water stewardship
- Waste management

Source: AstraZeneca Sustainability Report 2019
Environmental protection – impact

- Zero carbon emission commitment by 2025 (sites and fleet)
- 11% reduction in Scope 1 emissions
- 11% increase in our waste
- 62% of our electricity is renewable
- 18% reduction in our water use
- 97% of API discharges from direct suppliers demonstrated as safe

Source: AstraZeneca Sustainability Report 2019
Ethics and transparency
We have a bold ambition:
Create positive societal impact and promote ethical behaviour in all markets across our value chain

Supporting the UN Sustainable Development Goals

Equality and prosperity for all, fosters healthy societies
Our focus areas

- Ethical business culture
- Inclusion and diversity
- Talent and workforce evolution
- Workforce wellbeing and safety
- Responsible supply chain
- Human rights

Source: AstraZeneca Sustainability Report 2019
Ethics and transparency – impact

45.4% women in management roles

63.3 instances of non-compliance with the Code of Ethics per 1,000 employees

86% feel that AstraZeneca is a Great Place to Work

96 countries disclosing data points on Sustainability Transparency Map

89 manufacturing partners were evaluated

Source: AstraZeneca Sustainability Report 2019
Q&A panel

Leif Johansson
Non-Executive Chairman of the Board

Katarina Ageborg
Executive Vice-President, Sustainability and Chief Compliance Officer; President AstraZeneca AB, Sweden

Ashling Mulvaney
Head of Access to Healthcare

Jason Snape
Head of Environmental Protection

Heather Stewart
Head of Ethics and Transparency
Questions & Answers
Use of AstraZeneca conference call, webcast and presentation slides

The AstraZeneca webcast, conference call and presentation slides (together the ‘AstraZeneca Materials’) are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make available to the public, sell or otherwise reuse or commercialise the AstraZeneca Materials in any way. You may not edit, alter, adapt or add to the AstraZeneca Materials in any way, nor combine the AstraZeneca Materials with any other material. You may not download or use the AstraZeneca Materials for the purpose of promoting, advertising, endorsing or implying any connection between you (or any third party) and us, our agents or employees, or any contributors to the AstraZeneca Materials. You may not use the AstraZeneca Materials in any way that could bring our name or that of any Affiliate into disrepute or otherwise cause any loss or damage to us or any Affiliate. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA. Telephone +44 20 3749 5000, www.astrazeneca.com